as 3201 has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bril, V; Kuromiya, A; Kurono, M; Matsumoto, T; Nakamura, K; Ono, Y | 1 |
| Giannoukakis, N | 1 |
1 review(s) available for as 3201 and Diabetes Mellitus
| Article | Year |
|---|---|
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Humans; Pyrazines; Sorbitol; Spiro Compounds; Treatment Outcome | 2008 |
1 other study(ies) available for as 3201 and Diabetes Mellitus
| Article | Year |
|---|---|
Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus; Diabetic Neuropathies; Enzyme Inhibitors; Male; Neural Conduction; Pyrazines; Rats; Rats, Wistar; Sorbitol; Spiro Compounds; Streptozocin | 2008 |